BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 20001495)

  • 1. Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.
    Dohn LH; Jensen BV; Larsen FO
    Acta Oncol; 2010 Apr; 49(3):395-6. PubMed ID: 20001495
    [No Abstract]   [Full Text] [Related]  

  • 2. Dual biologic therapy in the first-line mCRC setting: implications of the CAIRO2 study.
    Chu E
    Clin Colorectal Cancer; 2008 Jul; 7(4):226. PubMed ID: 18650190
    [No Abstract]   [Full Text] [Related]  

  • 3. [The development of the first line treatment of metastatic colorectal cancer (mCRC)].
    Landherr L; Nagykálnai T
    Magy Onkol; 2009 Sep; 53(3):237-46. PubMed ID: 19793687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The feasibility of a short bevacizumab infusion in patients with metastatic colorectal cancer.
    Terazawa T; Nishitani H; Kato K; Hashimoto H; Akiyoshi K; Iwasa S; Nakajima TE; Hamaguchi T; Yamada Y; Shimada Y
    Anticancer Res; 2014 Feb; 34(2):1053-6. PubMed ID: 24511054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current role of bevacizumab in colorectal cancer.
    Saltz L
    Clin Adv Hematol Oncol; 2009 Jun; 7(6):375-6. PubMed ID: 19606071
    [No Abstract]   [Full Text] [Related]  

  • 6. [Progress of chemotherapy in colorectal cancer].
    Komatsu Y
    Gan To Kagaku Ryoho; 2007 Nov; 34(11):1771-6. PubMed ID: 18064761
    [No Abstract]   [Full Text] [Related]  

  • 7. [Metastatic colorectal cancer: adjournments from ESMO 2006].
    Bonetti A; Cascinu S; Falcone A; Maiello E; Zaniboni A; Aschele C
    Tumori; 2006; 92(6):1-12. PubMed ID: 17262903
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety of 10 min infusion of bevacizumab in combination with 5FU-based chemotherapy in non-selected metastatic colorectal cancer patients.
    Coriat R; Mir O; Chaussade S; Goldwasser F
    Dig Liver Dis; 2011 Mar; 43(3):248-9. PubMed ID: 21145299
    [No Abstract]   [Full Text] [Related]  

  • 9. Perforating dermatosis in a patient receiving bevacizumab.
    Vano-Galvan S; Moreno C; Medina J; Pérez-García B; García-López JL; Jaén P
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):972-4. PubMed ID: 19470057
    [No Abstract]   [Full Text] [Related]  

  • 10. Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer.
    Hochster HS
    Semin Oncol; 2006 Oct; 33(5 Suppl 10):S8-14. PubMed ID: 17145525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metastatic colorectal cancer: is surgery necessary?
    Schmidt C
    J Natl Cancer Inst; 2009 Aug; 101(16):1113-5. PubMed ID: 19671774
    [No Abstract]   [Full Text] [Related]  

  • 12. Update on capecitabine alone and in combination regimens in colorectal cancer patients.
    Silvestris N; Maiello E; De Vita F; Cinieri S; Santini D; Russo A; Tommasi S; Azzariti A; Numico G; Pisconti S; Petriella D; Lorusso V; Millaku A; Colucci G
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S46-55. PubMed ID: 21129610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
    Sogabe S; Komatsu Y; Yuki S; Kusumi T; Hatanaka K; Nakamura M; Kato T; Miyagishima T; Hosokawa A; Iwanaga I; Sakata Y; Asaka M
    Jpn J Clin Oncol; 2011 Apr; 41(4):490-7. PubMed ID: 21303790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Improving longevity in advanced intestinal cancer].
    Schmoll HJ
    Krankenpfl J; 2005; 43(1-3):48. PubMed ID: 15912837
    [No Abstract]   [Full Text] [Related]  

  • 15. [Evaluation of bevacizumab for advanced colorectal cancer].
    Naito M; Hoshino S; Noda N; Nakano M; Matsuo K; Yamauchi Y; Shinohara T; Tanaka S; Yamashita Y
    Gan To Kagaku Ryoho; 2010 Jan; 37(1):83-8. PubMed ID: 20087037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer.
    Vaidyanathan G; Groman A; Wilding G; Fakih MG
    Oncology; 2010; 79(1-2):67-71. PubMed ID: 21071992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colorectal cancer: to stack or sequence therapy?
    Azvolinsky A
    J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25957442
    [No Abstract]   [Full Text] [Related]  

  • 18. Common side effects and interactions of colorectal cancer therapeutic agents.
    Holt K
    J Pract Nurs; 2011; 61(1):7-20. PubMed ID: 21751717
    [No Abstract]   [Full Text] [Related]  

  • 19. The use cetuximab after oxaliplatin-based chemotherapy in a patient with metastatic colorectal cancer.
    Malik Z; Eng C
    Clin Adv Hematol Oncol; 2007 Jan; 5(1 Suppl 1):4-7. PubMed ID: 17491584
    [No Abstract]   [Full Text] [Related]  

  • 20. Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancer.
    Heinemann V; Hoff PM
    Oncology; 2010; 79(1-2):118-28. PubMed ID: 21088438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.